About Absci
AbSci improves protein expression and biomanufacturing in the biotech industry with its advanced platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system for precise control over protein production. Its notable product, SoluPure, simplifies protein purification without chromatography, speeding up the process and reducing costs. AbSci stands out by offering proprietary technologies that enhance drug discovery and manufacturing, aiming to replace traditional methods with more efficient solutions. The company's goal is to challenge established practices and create tools that improve the production of life-changing biologics.
Vancouver, WashingtonHeadquarters
2011Year Founded
$221.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Company Equity
Employee Stock Purchase Plan
Risks
Increased competition from AI-driven drug discovery firms may dilute market share.
Dependence on tech partnerships like AMD poses risks if strategic focus shifts.
Regulatory challenges could delay market entry for novel therapeutics with nonstandard amino acids.
Differentiation
Absci uses AI and synthetic biology for novel protein-based drug discovery.
Their SoluPure method simplifies protein purification, reducing production time and costs.
Absci's Integrated Drug Creation™ Platform combines target discovery and biomanufacturing in one process.
Upsides
Partnership with AMD enhances AI capabilities, boosting drug discovery efficiency.
Collaboration with Owkin could lead to first-in-class therapeutics in immuno-oncology.
Strategic alliance with MSK accelerates entry into the oncology market with novel therapeutics.
Funding
Total raised$221.68 M
Latest valuation$1.40 B
StageIPO
POST IPO EQUITY
12/31/2024$20
IPO
6/30/2021$200
$1.40 BLATE VC
2/28/2021$125
$625.00 M$65
$325.00 MDEBT
12/31/2019$5
SERIES D
12/31/2019$10
$52.00 MSERIES C
4/30/2018$12
$60.00 MSERIES A
1/31/2016$5
$25.50 M